KittyBruno
02-26

$BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC)$'s rise in the biotech industry is truly remarkable!

It's projected that by 2025, the company will achieve positive GAAP operating profit, marking a milestone event that will elevate its standing in the industry. What's even more impressive is that BeiGene's market cap has surpassed that of Heng Rui Medicine for the first time, showcasing its growing market dominance.

Its core product, Bruton’s tyrosine kinase (BTK) inhibitor Zanubrutinib, has seen strong performance, with sales reaching 12.9 billion RMB in the first three quarters of 2024, a 91% year-on-year growth.

Additionally, the approval of Tislelizumab for gastric cancer in the U.S. has helped push its overseas revenue above 50%. With such strong fundamentals, BeiGene's future looks incredibly promising!

Winning Trades
Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment